SHC
Sotera Health Co
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeSotera Health beat adjusted EPS estimates but missed revenue guidance slightly, with the stock falling 6.7% post-earnings due to weakening European medical device demand and flat Q4 revenue guidance despite maintained full-year outlook. Multiple analyst downgrades (JPMorgan to Underweight, Wall Street Zen from Strong Buy to Buy) reflect growing caution about end-market headwinds, though consensus remains Moderate Buy.
Red flags
- •Softening European medical device demand noted in mid-to-late Q3 and persisting into early Q4
- •Guidance for flat sequential revenue in Q4 suggests demand deceleration
- •Nordion segment revenue declined 12.4% due to Cobalt-60 shipment timing uncertainties
- •JPMorgan downgrade to Underweight citing heightened uncertainty in medtech end-market
- •Sharp 6.7% stock sell-off post-earnings despite EPS beat indicates market skepticism about forward guidance
- •Wall Street Zen downgrade from Strong Buy to Buy reflects reduced conviction
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Sachem Head Capital | SC 13G/A | −15.6M | 0.0% | -2.2% vs SPY -10.2% abs | 2026-10-09 | ↗ |
| Sachem Head Capital | SC 13G | NEW | 5.5% | +19.1% vs SPY +24.6% abs | 2026-05-15 | ↗ |